NEW YORK, September 22, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on the following
equities: Novavax, Inc. (NASDAQ: NVAX), Celgene
Corporation (NASDAQ: CELG), Achillion Pharmaceuticals,
Inc. (NASDAQ: ACHN), Mylan N.V. (NASDAQ: MYL),
Vascular Biogenics Ltd. (NASDAQ: VBLT). On Monday, September 21, 2015, NASDAQ ended at
4,828.95, up 0.04%, Dow Jones advanced 0.77%, to finish the day at
16,510.19, and the S&P closed at 1,966.97, up 0.46%. Register
for your complimentary reports at the links given below.
Novavax Inc
--
Novavax Inc's stock edged lower by 6.24% to close Monday's
session at USD 9.91. The company's
shares oscillated between USD 9.68 and USD
10.70 in trade during the day. The stock recorded a trading
volume of 7.11 million shares, which was above its 50-day daily
average volume of 5.25 million shares and above its 52-week average
volume of 4.52 million shares. Over the last three days, Novavax
Inc's shares have declined by 0.40% and in the past one week it has
moved up 1.64%. Furthermore, over the last three months, the stock
has lost 0.50% and in the past six months, the shares have picked
up 3.77%. On a compounded total return basis, the stock generated
negative return of 18.44% in the past one month. The stock is
trading at a price to book ratio of 6.87 while the historical PB
ratio is close to 6.17. Sign up and read the free notes on NVAX at:
http://www.aciassociation.com/NVAX.pdf
--
Celgene Corp
--
The stock of Celgene Corp lost 2.84% to close Monday's session
at USD 119.14. The shares of the
company moved in the range of USD
117.22 and USD 123.97. A
trading volume of 7.12 million shares was recorded, which was
greater than its 150-day daily average volume of 4.99 million
shares and above its 52-week average volume of 5.18 million shares.
Over the last five days, Celgene Corp's shares have declined by
2.51%. Additionally, in the past six months, the shares have
registered a loss of 3.09%. The company has returned 0.08% in the
past one month, and 1.64% in the last three months, on a compounded
total return basis. Further, the company is trading at a price to
earnings ratio of 45.13 and at a price to book ratio of 14.91. This
compares to a historical PE ratio of 46.76 and a historical PB
ratio close to 13.72. Register for free on ACI Association and
access the latest research on CELG at:
http://www.aciassociation.com/CELG.pdf
--
Achillion Pharmaceuticals Inc
--
Achillion Pharmaceuticals Inc's stock increased by 0.23% to
close Monday's session at USD 8.71.
The company's shares fluctuated in the range of USD 8.48 and USD
9.24 in trade during the day. A total of 6.12 million shares
exchanged hands, which surpassed its 50-day daily average volume of
2.59 million shares and was above its 52-week average volume of
4.56 million shares. Over the last three days Achillion
Pharmaceuticals Inc's shares have advanced 9.01% and in the past
one week it has moved up 11.95%. Furthermore, over the last three
months, the stock has lost 3.76% and in the past six months, the
shares have shed 19.69%. The stock is trading at a price to book
ratio of 4.25, which compares to a historical PB ratio close to
8.85. The complete research on ACHN is available for free at:
http://www.aciassociation.com/ACHN.pdf
--
Mylan NV
--
Mylan NV's stock slipped by 2.88% to close Monday's session at
USD 48.16. The company's shares
oscillated between USD 47.53 and USD
49.59. The stock recorded a trading volume of 6.08 million
shares, which was below its 50-day daily average volume of 8.02
million shares and below its 52-week average volume of 6.15 million
shares. Over the last five days, Mylan NV's shares have declined by
1.83%. In addition, over the last three months, the stock has lost
32.57% and year to date, the shares have shed 14.56%. The stock has
generated negative return of 6.49% in the past one month, and
positive return of 3.50% in the past one year, on a compounded
total return basis. Further, the company is trading at a price to
earnings ratio of 22.09 and a price to book ratio of 2.47. Free
in-depth research on MYL is available at:
http://www.aciassociation.com/MYL.pdf
--
VASCULAR BIOGENICS LTD
--
VASCULAR BIOGENICS LTD's stock advanced 18.25% to close Monday's
session at USD 8.10. The share price
vacillated between USD 7.00 and USD
8.37 in trade during the day. The stock recorded a trading
volume of 2.89 million shares, which was above its 50-day daily
average volume of 0.16 million shares and above its 52-week average
volume of 0.42 million shares. Over the last three days VASCULAR
BIOGENICS LTD's shares have advanced 51.12% and in the past one
week it has moved up 61.03%. Moreover, in the last three months,
the stock has gained 30.23% and year to date, the shares have
picked up 37.06%. The complimentary notes on VBLT can be downloaded
in PDF format at: http://www.aciassociation.com/VBLT.pdf
--
About ACI Association:
Active Charter Investors Association ("ACI Association")
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
equities listed on NYSE and NASDAQ and micro-cap stocks. ACI
Association has two distinct and independent departments. One
department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ACI Association has not been compensated; directly or
indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein.
NO WARRANTY
ACI Association, the Author, the Reviewer and the Sponsor
(collectively referred to as the "Publishers") are not responsible
for any error which may be occasioned at the time of printing of
this document or any error, mistake or shortcoming. No liability is
accepted by the Publishers whatsoever for any direct, indirect or
consequential loss arising from the use of this document. The
Publishers expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, the Publishers do not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The
included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ACI Association nor any party affiliated
with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our
report(s), read our disclosures, or for more information, visit
http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.aciassociation.com